Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma
Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Ariela Noy(Memorial Sloan Kettering Cancer Center), Eric Hedrick(Florida Hospital Cancer Institute), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Julie Teruya‐Feldstein(Memorial Sloan Kettering Cancer Center), Jing Qin(Memorial Sloan Kettering Cancer Center), André Goy(Hackensack University Medical Center), Craig H. Moskowitz(University of Miami), Carol S. Portlock(Memorial Sloan Kettering Cancer Center), David J. Straus(Memorial Sloan Kettering Cancer Center)
Cited by 151
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k